FHL2在慢性肾脏病动脉中膜钙化中的作用
本研究通过转录组分析和动物报告系统,发现FHL2是RUNX2的共激活因子,在CKD患者动脉血管平滑肌细胞中上调并核转位,与RUNX2相互作用促进成骨转分化;抑制FHL2可减轻尿毒症动物主动脉钙化且不影响骨骼。
要点
- FHL2在CKD动脉血管平滑肌细胞中表达上调并发生核转位。
- FHL2与RUNX2相互作用并作为其共激活因子促进成骨转分化。
- 抑制FHL2可减轻尿毒症动物主动脉钙化且不损害骨骼系统。
核心结论
- FHL2是治疗CKD患者动脉钙化的有前景的靶点。
研究设计与样本
- 研究采用人类数据转录组分析和动物报告系统筛选靶点,并在人类和动物CKD主动脉中验证FHL2表达。
- 通过共免疫沉淀和染色质免疫沉淀实验研究FHL2与RUNX2的转录机制。
- 在培养的血管平滑肌细胞中操作FHL2表达,检测其对高磷诱导转分化的影响。
- 使用FHL2缺失小鼠在体内证实FHL2在动脉中膜钙化发展中的作用。
主要发现
- 在所有潜在RUNX2辅因子中,FHL2在心血管系统中选择性表达。
- 在CKD受试者中,FHL2在动脉血管平滑肌细胞中上调并从细胞质转位至细胞核。
- 进入细胞核后,FHL2在结构和功能上与RUNX2相互作用,作为RUNX2的共激活因子。
- 抑制FHL2表达可避免血管平滑肌细胞向成骨表型转分化,并减轻尿毒症动物的主动脉钙化,且对骨骼系统无不良影响。
临床怎么用
- FHL2可作为治疗CKD患者动脉中膜钙化的潜在靶点,且抑制FHL2未对骨骼系统造成不良影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arterial medial calcification (AMC) is a common complication in individuals with chronic kidney disease (CKD), which can lead to cardiovascular morbidity and mortality. The progression of AMC is controlled by a key transcription factor called runt-related transcription factor 2 (RUNX2), which induces vascular smooth muscle cells (VSMCs) transdifferentiation into an osteogenic phenotype. However, RUNX2 has not been targeted for therapy due to its essential role in bone development. The objective of our study was to discover a RUNX2 coactivator that is highly expressed in arterial VSMCs as a potential therapy for AMC. METHODS: We employed transcriptomic analysis of human data and an animal reporter system to pinpoint four and a half LIM domains 2 (FHL2) as a potential target. Subsequently, we investigated the mRNA and protein expression patterns of FHL2 in the aortas of both human and animal subjects with CKD. To examine the role of FHL2 in the RUNX2 transcription machinery, we conducted coimmunoprecipitation and chromatin immunoprecipitation experiments. Next, we manipulated FHL2 expression in cultured VSMCs to examine its impact on high phosphate-induced transdifferentiation. Finally, we employed FHL2-null mice to confirm the role of FHL2 in the development of AMC in vivo. RESULTS: Among all the potential RUNX2 cofactors, FHL2 displays selective expression within the cardiovascular system. In the context of CKD subjects, FHL2 undergoes upregulation and translocation from the cytosol to the nucleus of arterial VSMCs. Once in the nucleus, FHL2 interacts structurally and functionally with RUNX2, acting as a coactivator of RUNX2. Notably, the inhibition of FHL2 expression averts transdifferentiation of VSMCs into an osteogenic phenotype and mitigates aortic calcification in uremic animals, without causing any detrimental effects on the skeletal system. CONCLUSION: These observations provide evidence that FHL2 is a promising target for treating arterial calcification in patients with CKD.
引用
- Liao YR, Tsai YC, Hsieh TH, et al. FHL2 in arterial medial calcification in chronic kidney disease. Nephrol Dial Transplant. 2024. PMID: 38664060. doi:10.1093/ndt/gfae091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。